Autologous fibrin sealant reduces pain after tonsillectomy.

OBJECTIVES/HYPOTHESIS: Pain is a major cause of morbidity after tonsillectomy. Although various efforts have been made to reduce pain, the use of oral analgesics, which can have adverse side effects, remains the standard of care. It is hypothesized that fibrin sealant, used to achieve hemostasis and enhance healing in many surgical procedures, might help decrease pain after this operation. STUDY DESIGN: A prospective, randomized, blinded study was performed on 20 children aged 5 to 17 years who were undergoing tonsillectomy, to evaluate the efficacy of FIBRIN SEALANT in reducing postoperative pain. METHODS: All patients pre-donated 40 mL of blood from which autologous concentrated fibrinogen was prepared by cryoprecipitation. In the fibrin sealant group, fibrinogen and topical bovine thrombin were sprayed onto the surgical site to form fibrin sealant at the conclusion of tonsillectomy. The 10 patients in the control group (C) received no fibrin sealant. Patients rated their level of pain immediately after surgery and at regular intervals for 3 days after surgery using the Wong-Baker Faces Pain Rating Scale (1-6). Emesis, postoperative bleeding, medications, and adverse events were also evaluated. RESULTS: At 7.00 P.M. on postoperative day (POD) 0, the mean +/- SD fibrin sealant group pain score (2.9+/-0.41 units) was significantly lower than for the C group (4.1+/-0.43 units; P < or = .05). There was also a trend in favor of less pain in the fibrin sealant group at 7:00 P.M. on POD 1, with a mean of 3.5+/-0.43 units versus 2.4+/-0.48 units for C (P = .15). The odds of a patient in C experiencing emesis were 8.16 times higher, (P < or = .05) than for patients in the fibrin sealant group. CONCLUSIONS: Fibrin sealant significantly reduced pain the evening after pediatric tonsillectomy and also decreased the chance of experiencing emesis. Thus fibrin sealant may be clinically useful as an adjunct to tonsillectomy.

Hemolysis during leukocyte-reduction filtration of stored red blood cells.

Hemolysis has been reported in red blood cells (RBCs) that have undergone leukocyte-reduction filtration. This study investigated whether the age of RBCs or the filter type affected hemolysis. One hundred eighty units of RBCs (adenine-saline added) were leukocyte-reduced by filtration. At each of the 6 weeks of shelf life, 10 units were filtered with the "BPF4" filter, 10 units with the "Purecell RCQ" filter, and 10 units with the "Sepacell" filter. Filtration was performed with strict adherence to the manufacturers' directions. Pre- and post-filtration samples were assayed for plasma hemoglobin by measuring the plasma absorbances at 578 nm and 562 nm. The increase of plasma hemoglobin concentration following filtration was significantly greater (p < 0.05) in older units, compared to fresher units, when the Sepacell and BPF4 filters were used. For example, the increase of plasma hemoglobin at week 6 (83.47 mg/dl:Sepacell, 128.93 mg/dl BPF4) was significantly greater than at week 1 (7.07 mg/dl Sepacell, 4.77 mg/dl BPF4) (Sepacell: p=0.008; BPF4: p=0.006). For units stored 1, 2, 4, 5, or 6 weeks, the increase of plasma hemoglobin concentration post-filtration was significantly greater with the BPF4 filter, compared to the Purecell RCQ filter (p <0.045); for units stored 5 weeks, the increase in plasma hemoglobin concentration post-filtration was significantly greater with the BPF4 filter compared to the Sepacell filter (p = 0.009). Mean filtration times were significantly longer in older units compared to fresh units. This study shows that increased storage duration of RBCs (adenine-saline added) is attended by greater hemolysis during leukocyte-reduction filtration and by prolongation of the filtration time. In addition, the amount of hemolysis may be influenced by the type of filter.